The global healthcare bioconvergence market size accounted for USD 140.85 billion in 2024, grew to USD 152.03 billion in 2025 and is projected to surpass around USD 302.4 billion by 2034, representing a healthy CAGR of 7.94% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Healthcare Bioconvergence Market
5.1. COVID-19 Landscape: Healthcare Bioconvergence Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Healthcare Bioconvergence Market, By Application
8.1. Healthcare Bioconvergence Market, By Application, 2020-2027
8.1.1. Drug Discovery
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Nanorobotics for Drug Discovery
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Regenerative Medicine
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Diagnostic and Biological Sensor
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Bioelectronics
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Engineered living materials
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Optogenetics
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Precision Medicine
8.1.8.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Healthcare Bioconvergence Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Application (2021-2034)
9.1.2. U.S.
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, By Application (2021-2034)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Application (2021-2034)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, By Application (2021-2034)
9.2.3. France
9.2.3.1. Market Revenue and Forecast, By Application (2021-2034)
9.2.4. Rest of Europe
9.2.4.1. Market Revenue and Forecast, By Application (2021-2034)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Application (2021-2034)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, By Application (2021-2034)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, By Application (2021-2034)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, By Application (2021-2034)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, By Application (2021-2034)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Application (2021-2034)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, By Application (2021-2034)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, By Application (2021-2034)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, By Application (2021-2034)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, By Application (2021-2034)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Application (2021-2034)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, By Application (2021-2034)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, By Application (2021-2034)
Chapter 10. Company Profiles
10.1. BiomX
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Singota Solutions
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Anima Biotech Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Ginkgo Bioworks.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. SetPoint Medical Corporation
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Zymergen Inc.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Galvani Bioelectronics
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. BICO - The Bio Convergence Company
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
Chapter 11. Research Methodology
11.1.Primary Research
11.2. Secondary Research
11.3.Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample